company background image
CNTA logo

Centessa Pharmaceuticals NasdaqGS:CNTA Stock Report

Last Price

US$13.75

Market Cap

US$1.6b

7D

-6.0%

1Y

104.0%

Updated

11 Sep, 2024

Data

Company Financials +

Centessa Pharmaceuticals plc

NasdaqGS:CNTA Stock Report

Market Cap: US$1.6b

CNTA Stock Overview

A clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients.

CNTA fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Centessa Pharmaceuticals plc Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Centessa Pharmaceuticals
Historical stock prices
Current Share PriceUS$13.75
52 Week HighUS$17.25
52 Week LowUS$5.15
Beta1.45
11 Month Change30.33%
3 Month Change38.47%
1 Year Change104.01%
33 Year Change-33.93%
5 Year Changen/a
Change since IPO-36.78%

Recent News & Updates

Centessa Pharmaceuticals (NASDAQ:CNTA) Has Debt But No Earnings; Should You Worry?

Aug 15
Centessa Pharmaceuticals (NASDAQ:CNTA) Has Debt But No Earnings; Should You Worry?

Recent updates

Centessa Pharmaceuticals (NASDAQ:CNTA) Has Debt But No Earnings; Should You Worry?

Aug 15
Centessa Pharmaceuticals (NASDAQ:CNTA) Has Debt But No Earnings; Should You Worry?

Centessa: Hemophilia B Data Readout In 2024 Is Major Turning Point

Apr 24

Health Check: How Prudently Does Centessa Pharmaceuticals (NASDAQ:CNTA) Use Debt?

Mar 07
Health Check: How Prudently Does Centessa Pharmaceuticals (NASDAQ:CNTA) Use Debt?

Centessa Pharmaceuticals snaps multi-day losing streak; up 10%

Oct 20

Centessa hemophilia B therapy SerpinPC gets FDA orphan drug status

Sep 14

Centessa Pharmaceuticals GAAP EPS of -$0.69

Aug 10

Checking In On Centessa Pharmaceuticals

Dec 23

Centessa Pharmaceuticals stock pops 20%+ intraday to post-IPO high

Jun 14

Shareholder Returns

CNTAUS BiotechsUS Market
7D-6.0%1.3%0.3%
1Y104.0%16.5%21.7%

Return vs Industry: CNTA exceeded the US Biotechs industry which returned 15.1% over the past year.

Return vs Market: CNTA exceeded the US Market which returned 20.5% over the past year.

Price Volatility

Is CNTA's price volatile compared to industry and market?
CNTA volatility
CNTA Average Weekly Movement9.1%
Biotechs Industry Average Movement10.4%
Market Average Movement6.3%
10% most volatile stocks in US Market15.1%
10% least volatile stocks in US Market3.1%

Stable Share Price: CNTA's share price has been volatile over the past 3 months.

Volatility Over Time: CNTA's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
202072Saurabh Sahawww.centessa.com

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy.

Centessa Pharmaceuticals plc Fundamentals Summary

How do Centessa Pharmaceuticals's earnings and revenue compare to its market cap?
CNTA fundamental statistics
Market capUS$1.56b
Earnings (TTM)-US$157.35m
Revenue (TTM)US$6.85m

227.4x

P/S Ratio

-9.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CNTA income statement (TTM)
RevenueUS$6.85m
Cost of RevenueUS$0
Gross ProfitUS$6.85m
Other ExpensesUS$164.20m
Earnings-US$157.35m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-1.39
Gross Margin100.00%
Net Profit Margin-2,296.03%
Debt/Equity Ratio26.7%

How did CNTA perform over the long term?

See historical performance and comparison